Royalty Report: Drugs, Pharmaceuticals, Disease – Collection: 28715


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 7


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Disease
  • Therapeutic
  • Ophthalmological
  • Biotechnology
  • Cancer
  • Osteoarthritis

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 28715

License Grant
Pursuant to an acquisition agreement, the Party entered into a License Agreement, in which Can-Fite granted the Licensee a sole and exclusive worldwide License for the use of CF101.
License Property
CF101 (known generically as IB-MECA), is being developed to treat three ophthalmic indications dry eye syndrome; glaucoma and uveitis. We are currently (i) conducting a Phase III trial with respect to the development of CF101 for dry eye syndrome, under an Investigational New Drug, or IND, application with the United States Food and Drug Administration, or FDA; (ii) conducting a Phase II trial with respect to the development of CF101 for the treatment of glaucoma; and (iii) preparing for Phase II study of the development of CF101 for uveitis.
CF101 is a highly-selective, orally bioavailable small molecule synthetic drug, which targets the A3 adenosine receptor (A3AR). We believe that CF101 has a favorable safety profile and a potent anti-inflammatory activity, mediated via its capability to inhibit the production of inflammatory cytokines, such as TNF-a, MMPs, IL-1, and IL-6. This is mediated by activation of the A3AR, which is highly expressed in inflammatory tissues in contrast to normal tissues where expression levels of the receptor are very low. We believe that the anti-inflammatory and neuroprotective effects of CF101 make it an attractive candidate for use in the treatment of a variety of ophthalmic diseases.
Field of Use
The field of ophthalmic diseases.

IPSCIO Record ID: 4190

License Grant
The Israeli Licensor has agreed to grant the Licensee an exclusive worldwide License for its therapeutic drug in the field of ophthalmic diseases in return for which we have agreed to grant shares and warrants representing approximately 90% of the issued share capitalization of our company.  

The Licensee will be granted to an Israeli subsidiary of the Licensor which will be transferred in whole to us at closing.

License Property
The drug, CF101 (known generically as IB-MECA), is being developed to treat three ophthalmic indications dry eye syndrome; glaucoma and uveitis.
Field of Use
Concurrently with the closing the Licensee is required to enter into a service Agreement with the Licensor or its affiliate for the management of all activities relating to the pre-clinical and clinical studies to be performed for the development of the drug.

IPSCIO Record ID: 3522

License Grant
Licensee was granted an exclusive license for the use of a family of U.S. and European patents and patent applications relating to CF101, CF102 and other small molecules and for the use, sale, production and distribution of products derived from such patents around the world. Licensor is a national research organization.
License Property
CF101 and CF102 are being developed to treat several autoimmune-inflammatory, oncological and ophthalmic indications. They are synthetic A3AR agonists. A3ARs have significant expression in tumor and inflammatory cells, whereas normal cells have low or no expression of this receptor. The A3AR agonists and allosteric modulators bind with high selectivity and affinity to the A3ARs and upon binding to the receptor initiate down-stream signal transduction pathways resulting in apoptosis, or programmed cell death, of tumors and inflammatory cells and to the inhibition of inflammatory cytokines. Cytokines are proteins produced by cells that interact with cells of the immune system in order to regulate the body’s response to disease and infection. Overproduction or inappropriate production of certain cytokines by the body can result in disease.

IPSCIO Record ID: 179836

License Grant
The Israeli Licensor hereby grants to the Israeli Licensee a non-transferable sole and exclusive license, with the right to sublicense under the EYEFITE Patent Rights and CANFITE Know-How, to make, have made, use, sell, offer to sell, import, research, develop, commercialize and otherwise exploit the Licensed Compound and Licensed Product in the Field in the Territory.
License Property
'Licensed Compound' means CF101.

'CF101' means the adenosine A3 receptor agonist designated by the Licensor as CF101, and known generically as IB-MECA (Methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl]- β-D-Ibofuronamid).

US3 11/604,905 28-Nov-06 Issued Patent, Serial No. 7,825,102

US* 12/450,094 13-Mar-08 Pending

Field of Use
'Field' means the treatment of any ophthalmic disease, disorder and conditions in humans.

IPSCIO Record ID: 7639

License Grant
The Israel Licensor signed an Agreement regarding the provision of a License for its CF101 drug with a South Korean pharmaceutical Licensee. The Licensor granted a License to use, develop and market its CF101 drug for treating only rheumatoid arthritis only in the Republic of Korea.
License Property
CF101 drug for treating only rheumatoid arthritis only.
Field of Use
The Licensee researches and develops over the counter and prescription drugs in South Korea.

IPSCIO Record ID: 366163

License Grant
Licensor will grant French Licensee an exclusive option to purchase its license of Piclidenoson in the veterinary osteoarthritis market for two years from the signature date, during which time Licensee will conduct proof-of-concept studies and cover all associated costs.
License Property
Piclidenoson, generically known as IB-MECA (methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl]-b-D-ribofuronamide), is an oral small molecule drug formulated in a tablet. Piclidenosons mechanism of action is A3AR mediated and includes modulation of key signaling proteins, such as PI3K, PKA, PKB/Akt, IKK and NF-kB, resulting in deregulation of the Wnt/ß-catenin pathway and inhibition of inflammatory cytokine production.
Field of Use
Field of use for the treatment of osteoarthritis in companion animals including dogs and cats.

IPSCIO Record ID: 7532

License Grant
Licensor hereby grants to Licensee during the term of this Agreement a sole and exclusive license, even as against Licensor, under the Licensed Technology (i) to develop, import and use the Ingredient in the Field in the Territory, and (ii) to develop, have developed, register, market, have marketed, produce, have produced, distribute, have distributed, sell, have sold, offer for sale and import the Product in the Field in the Territory, and (iii) to have produced the Product outside the Territory for sale of such Product in the Field in the Territory. Such right granted to Licensee shall include Licensee's right under the Licensed Technology to conduct research on doses, formulations and dosage forms of the Product.
License Property
Licensed product is CF101 for autoimmune inflammatory indications
Field of Use
“Field” shall mean systemic use (oral and injectable) of the Product for the therapeutic treatment of inflammatory diseases in humans; provided, however, that notwithstanding the foregoing, Licensee shall not sell Product that is labeled for ophthalmic use.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.